— Know what they know.
Not Investment Advice
Also trades as: ALNOV.PA (PAR) · $vol 0M · NCYT.L (LSE) · $vol 0M

NVYTF OTC

Novacyt S.A.
1W: +0.0% 1M: +0.0% 3M: +19.0% YTD: +19.0% 1Y: +14.0% 3Y: -30.2%
$0.57
+0.00 (+0.00%)
 
OTC · Healthcare · Medical - Devices · Tech Score Buy · Power 60 · $41.4M mcap · 70M float · 0.0000% daily turnover · Short 100% of daily vol
Smart Money Score
No convergence signal
Key Statistics
Market Cap$41.4M
52W Range0.48-0.571
Volume830
Avg Volume12
Beta1.11
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOLyn Dafydd Rees
Employees234
SectorHealthcare
IndustryMedical - Devices
IPO Date2021-01-08
131 Boulevard Carnot
Le Vésinet, IF 78110
FR
33 1 39 46 51 04
About Novacyt S.A.

Novacyt S.A., along with its subsidiaries, specializes in the global development, manufacturing, bespoke design, and commercialization of diagnostic products. These offerings are instrumental in identifying cancer and infectious diseases, reaching markets across the United Kingdom, Europe, the United States, Asia Pacific, the Middle East, and Africa. The company's activities are organized into three primary divisions: Primer Design, Lab21 Products, and IT-IS International. Primer Design is responsible for conceiving, producing, and distributing molecular real-time qPCR testing equipment and reagents specifically for infectious disease diagnosis. Lab21 Products focuses on crafting and delivering a spectrum of protein-based in-vitro diagnostic (IVD) solutions for infectious ailments. Lastly, IT-IS International develops and manufactures PCR devices catering to both the life sciences and food testing industries. Novacyt's customer base includes hospitals and various corporate entities. Founded in 2006, the firm is headquartered in Vélizy-Villacoublay, France.

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms